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Pituitary function has been shown to be regulated by an increasing number of factors, including
cytokines and hormones, such as TNF and T3. Both the proinflammatory cytokine TNF and T3
have been suggested to be involved in the maintenance of tissue homeostasis in the anterior
pituitary gland. In this report we show that T3 negatively interferes with MAPK p38 and nuclear
factor-B (NF-B) activation by TNF in GH4C1 cells. Our data demonstrate that MAPK p38 is
specifically activated upon exposure to TNF and that T3 abolishes this activation in a time-
dependentmanner by amechanism that involves the induction of theMAPKphosphatase, DUSP1.
Our data show that the pool of up-regulated DUSP1 by T3 is mainly localized to the cytosol, and
that TNF does not affect this localization. On the other hand, we show that T3 impairs the
activation of the NF-B pathway induced by TNF, producing a significant decrease in NF-B-depen-
dent transcription, phosphorylation of IB, translocation of p65/NF-B to the nucleus, andp65/NF-B
transactivation potential. Interestingly, the overexpression of DUSP1 inhibits the NF-B activation
achieved by either TNF or ectopic expression of the upstream inducer of MAPK p38. Conversely,
DUSP1depletion abrogates the inhibitory effect of T3 on the induction ofNF-B-dependent transcrip-
tion by TNF. Overall, our results indicate that T3 antagonizes TNF signaling in rat pituitary tumor
cells through the induction of DUSP1. (Molecular Endocrinology 24: 412–422, 2010)
The thyroid hormone T3 influences a variety of physi-ological processes in mammals, including cell growth
and metabolism (1). Most, if not all, of these actions are
mediated by nuclear T3 receptors, which are widely ex-
pressed in mammalian tissues. Pituitary somatolacto-
trope cells are a well established target of T3, andGH4C1
cells, which are derived from a rat pituitary tumor, have
been widely used as a model to understand the mecha-
nisms of T3 action (2).
TNF is a proinflammatory cytokine that regulates
cell proliferation, differentiation, and apoptosis and in-
duces production of other cytokines (3). TNF is mainly
produced by macrophages, but also by a broad variety of
other tissues, including the pituitary, in particular by the
intermediate lobe and by the somatotroph cells (4, 5). The
presence of TNF receptors has also been reported both
in normal pituitary cells (6, 7) and in the pituitary GH3
cell line (8), suggesting that this cytokine might well play
a role as an autocrine or paracrine regulator of the pitu-
itary cell function. Indeed, TNF has been suggested to be
involved in the maintenance of tissue homeostasis in the
anterior pituitary gland (8) and is likely to be a major
paracrine modulator of lactotroph function (9).
In many cell types, TNF affects different cellular
functions by regulating the phosphorylation cascade of
members of the MAPK family, in particular the stress
kinases, c-Jun N-terminal kinase (JNK) and MAPK p38
(10). The activation of MAPK is tightly regulated by
MAPK phosphatases, which dephosphorylate MAPK at
Thr/Tyr residues critical for activation, thereby contrib-
uting to the down-regulation of MAPK activity. DUSP1,
also known as MAPK phosphatase 1 (MKP1), the founder
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member of this family, is induced by a variety of stimuli
including growth factors, nuclear receptors, and stress
stimuli (11), and localizes to the nucleus through a
LXXLL motif in its amino terminus (12). The balance
between the activation and the inactivation of MAPK is a
critical determinant of biological outcomes in many cell
types. For example,MAPK p38 activation in the pituitary
has been shown to regulate GH gene transcription and
expression (13, 14) or the GnRH-signaling cascade (15).
TNF can also exert its effects by triggering the acti-
vation of nuclear factor-B (NF-B)-signaling cascade
(10). NF-B transcription factors consist of dimers assem-
bled from p50 and p65 subunits, which are normally
found in the cytosol, retained by interaction with an in-
hibitory molecule called IB. Activation of IB kinases
(IK) leads to phosphorylation and degradation of IB,
allowing nuclear translocation of NF-B dimers, where
they regulate target gene transcription (16). It has been
shown previously that TNF activates NF-B in pituitary
GH3 cells (9, 17) and that this activation can be blocked
by coexpressing dominant-negative isoforms of compo-
nents of the NF-B-signaling pathway (9).
Interestingly, TNF can simultaneously activate both
MAPKp38 andNF-B pathways in different cellular con-
texts. For example, it has been previously described that
MAPK p38 is required for NF-B-dependent gene expres-
sion (18, 19) and contributes to TNF-dependent NF-B
activation through the downstream effector, mitogen-
and stress-associated protein kinase 1 (MSK1) (20). The
activation of MAPK and/or NF-B pathways by TNF
switches many key proapoptotic, antiapoptotic, prolifer-
ative, or inflammatory genes that result in the desired
cellular responses. Many ligands of different nuclear re-
ceptors have been shown to inhibit TNF signaling.
Among them, dexamethasone is widely used as TNF
antagonist in diverse cellular contexts (21). To a lesser
extent, other nuclear receptors such as the peroxisome
proliferator-activated receptor  (22) or the androgen re-
ceptor (23) negatively interfere with inflammatory gene
expression triggered by the activation of TNF-signaling
pathway. Interestingly, the progesterone receptor an-
tagonizes the permissive action of estrogens on TNF-
induced apoptosis of anterior pituitary cells, whereas
dexamethasone fails to do it (24). However, no evidence
of regulation of TNF effects by T3 receptors has been
described so far.
We have recently reported that T3 induces the expres-
sion of DUSP1 in pituitary GH4C1 cells by a posttran-
scriptional mechanism (25). In this study, we have ana-
lyzed the possibility that T3 could also affect the response
of these cells to TNF, and we show for the first time that
T3 blocks the effects of the cytokine on both phosphory-
lation of MAPK p38 and NF-B activity. The inhibitory
effect of T3 on the TNF pathway involves the up-regu-
lation of the cytosolic pool of DUSP1, which, in turn,
impairs the phosphorylation of MAPK p38 achieved by
TNF. Moreover, DUSP1 also controls the induction of
NF-B pathway by either TNF or ectopic expression of
the upstream inducer of MAPK p38 in GH4C1 cells.
Given the crucial role of TNF in several physiopatho-
logical processes, deregulation of TNF function by T3 is
likely to be biologically important in the pituitary.
Results
T3 selectively inhibits TNF-mediated activation of
MAPK p38 and induces the expression of DUSP1
TNF exerts its effects through the regulation of
MAPK-signaling pathway in different cellular contexts.
Considering that this cytokine plays a pivotal role in the
maintenance of the homeostasis in the pituitary, our first
aim was to test whether TNF was able to regulate
MAPK activation in pituitary cells. To that purpose, we
first analyzed the phosphorylation level of the classical
MAPK (ERK, JNK, andMAPKp38), after treatmentwith
TNF by using phospho-specific antibodies. As shown in
Fig. 1A, MAPK p38 was phosphorylated in response to
TNF in a time-dependent manner, showing a peak of
activation at 15 min incubation. By contrast, TNF did
not induce the phosphorylation level of either ERK or
JNK (data not shown). The lack of induction of JNK by
TNFwas confirmed by kinase assays using c-Jun as sub-
strate (data not shown). Different nuclear receptors have
been shown to block the activation of MAPK-signaling
pathways; therefore, we next investigated the effect of T3
on MAPK phosphorylation after TNF treatment. For
these experiments, MAPK phosphorylation levels were
measured by Western blotting in cells pretreated with T3
for different times and with TNF for the last 15 min. As
shown in Fig. 1B, T3 blocked TNF-induced MAPK p38
phosphorylation in a time-dependent manner. By con-
trast, T3 did not affect the low levels of the phosphory-
lated ERK or JNK under the same conditions (Fig. 1B).
DUSP1 is a phosphatase that regulates MAPK activity
by controlling its phosphorylation state in diverse cell
lines. Furthermore, we have previously reported that T3
can induce DUSP1 levels in pituitary cells (25). Therefore,
we next tested whether T3 was able to regulate TNF-
mediated activation of MAPK p38 phosphorylation
through the induction of DUSP1 in pituitary cells. To test
this hypothesis, we first measured the levels of DUSP1
after T3 treatment up to 24 h. The expression of DUSP1
protein was induced rapidly by incubation with T3 and
was sustained for at least 24 h (Fig. 1C). Because it has
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been generally accepted that DUSP1 localizes to the nu-
cleus (12), we next investigated the subcellular localiza-
tion of DUSP1 after T3 treatment with or without TNF.
Surprisingly, control GH4C1 cells showed low expres-
sion of DUSP1 in cytosolic fractions, whereas the levels of
DUSP1 in nuclear extracts were almost undetectable (Fig.
1D). Moreover, the pool of up-regulated DUSP1 by T3
was mainly localized to the cytosol, and the treatment of
the cells in the presence of TNF did not induce major
changes in the subcellular distribution of DUSP1 both in
control and T3-treated cells (Fig. 1D).
We next investigated whether DUSP1 was involved in
the regulation of MAPK p38 activity by T3. To address
this question, cells were transiently transfectedwith either
siControl [a control small interfering RNA (siRNA)] or
with two specific siRNAs to knock down DUSP1 expres-
sion (siDUSP1), as previously described (25). After incu-
bation in the absence or presence of T3, and/or TNF, the
levels of DUSP1 mRNA were monitored by quantitative
RT-PCR (QRT-PCR). The siDUSP1 reduced DUSP1
mRNA levels by about 80% of those found in cells
transfected with the siControl, without any effect of
the treatments (Fig. 2A). Figure 2B shows that although
T3 markedly reduced the induction of MAPK p38 phos-
phorylation by TNF in cells transfected with siControl,
the effect of T3 was blunted in the cells transfected with
the specific siDUSP1. These data demonstrate that DUSP1
mediates the inhibition of TNF-induction of MAPK p38
activity caused by T3 in GH4C1 cells.
T3 blocks the NF-B pathway induced by TNF
TNF effects are mediated, not only by regulating
MAPK pathways, but also by activation of the NF-B
pathway in diverse cell types. Because NF-B is a known
downstream target of MAPK p38 and we have recently
shown that T3 blocks the activity of the NF-B pathway
in serum-deprived-GH4C1 cells (25), we tested whether
T3 was also able to prevent the effects of TNF on NF-B
activation. For this purpose, GH4C1 cells were tran-
siently transfected with a thymidine kinase (TK)-Luc re-
porter containing three repeats of the NF-B consensus-
binding sequence (3NF-B-Luc). Treatment of the cells
with TNF for 6 h caused a significant increase in lucif-
erase activity, and preincubation for 24 hwith T3 reduced
TNF-mediated activation by about 50% (Fig. 3A). By
contrast, the TK-Luc control reporter showed a low ac-
tivity, which was not modified in the presence of either
TNF or T3 (Fig. 3A). NF-B may be activated by stim-
ulation of the transactivation domain in the p65/NF-B
subunit. Therefore, we studied whether the differences
observed after T3 treatment were also dependent on the
transcriptional activity of p65/NF-B. To address this
question, we used a plasmid encoding the Gal4-p65 fu-
sion protein, in which the sequences encoding the DNA-
binding domain of Gal4 have been fused with sequences
encoding p65/NF-B. Its cotransfection with a Gal4-Luc
reporter plasmid allowed us to determinewhether cellular
signals triggered by TNF and T3 regulate gene expres-
sion by specifically targeting the p65/NF-B protein. Like
NF-B-dependent transcription, TNF increased the
basal activity ofGal4-p65 about 8-fold, and incubation of
the cells with T3 decreased it by about 50% (Fig. 3B). By
FIG. 1. T3 selectively inhibits TNF-mediated activation of MAPK p38
and induces the expression of DUSP1. A, GH4C1 cells were incubated
with TNF (10 ng/ml) for different times, and total cell lysates were
analyzed by Western blotting with antibodies against phosphorylated
and total MAPK p38. B, Cells were treated with T3 (5 nM) for different
times and then incubated with 10 ng/ml TNF for the last 15 min.
Total cell lysates were prepared and analyzed by Western blotting with
antibodies against the phosphorylated and total forms of the three
MAPKs. The blots shown are from a representative experiment
performed twice with similar results. C, Cells were incubated with T3
(5 nM) for different times, and the total cell extracts were analyzed by
Western blotting using antibodies against DUSP1. Equal protein
loading was evaluated by assessing -actin. D, Cells were maintained
in the presence or absence of T3 (5 nM) for 24 h and then incubated
with 10 ng/ml TNF for 15 min. The cytosolic extracts (CE) and the
nuclear extracts (NE) were analyzed by Western blotting using
antibodies against DUSP1. The levels of tubulin and poly ADP ribose
polymerase (PARP) were used as controls to validate the integrity of
the cytosolic and nuclear fractions, respectively.
FIG. 2. DUSP1 controls the T3-mediated inhibition of TNF-induced
MAPK p38. GH4C1 cells were transfected with the siControl or with
the siDUSP1, incubated for 24 h with T3, and then stimulated with TNF
for 15 min. A, Total RNA was extracted, and the levels of DUSP1 mRNA
were monitored by QRT-PCR. DUSP1 mRNA levels were normalized with
glyceraldehyde-3-phosphate dehydrogenase mRNA levels, and the
results are expressed as the fold change in mRNA expression. The
values represent the mean  SD. B, Total cell lysates were prepared and
analyzed by Western blotting with antibodies against phospho-p38
and total p38. The blots shown are from a representative experiment
performed twice with similar results.
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contrast, the Gal4 control reporter activity was not mod-
ified in the presence of either TNF or T3 (Fig. 3B). These
results indicate that TNF activates the NF-B transcrip-
tional activity by increasing p65/NF-B transactivation,
and that T3 is able to decrease this effect. However, in
agreement with our previous results (25), it seems that T3
is not only blocking TNF-mediated induction of NF-B,
because it also significantly inhibits the basal activity of
both NF-B-dependent transcription (Fig. 3A) and p65
transactivation (Fig. 3B).
As mentioned previously, NF-B is regulated, in part,
by a cellular process that involves phosphorylation and
degradation of its inhibitory subunit IB, permitting ac-
tive NF-B complexes to translocate to the nucleus and
activate transcription. Thus, we measured the kinetics of
IB degradation in cytosolic cell extracts upon exposure
to TNF in the absence or presence of T3. As expected,
incubation of the cells with TNF produced a transient
decrease of IB levels, whichwere not significantlymod-
ified by treatment with T3 (Fig. 3C).We next analyzed the
effect of TNF and T3 on IB phosphorylation and
showed that phosphorylated IB levels transiently in-
creased after TNF treatment, whereas T3 abrogated this
effect (Fig. 3C).We then examined the effect of TNF and
T3 on p65/NF-B levels in nuclear extracts and found that
p65/NF-B levels increased after TNF incubation in
control cells. However, the translocation of p65/NF-B to
the nucleus induced by TNF was strongly reduced after
24 h exposure to T3. In contrast, p65/NF-B levels in
cytosolic extracts remained quite high and unchanged in
the presence of T3 (Fig. 3C).
Because we detected differences in the levels of nuclear
p65/NF-B after exposure to T3, we determined the NF-
B-binding activity in nuclear extracts from cells that
were incubated with T3 for 24 h and then with TNF for
the indicated time periods (Fig. 3D). Specific NF-B-
DNA-binding complexes were observed when cells were
incubated in the presence of TNF for 15 min to 6 h,
whereas complex formation was reduced when these cells
were previously exposed to T3. However, although T3
treatment appears to reduce complex formation, signifi-
cant translocation into the nuclear compartment is still
observed in the presence of T3.
T3 blocks the NF-B pathway induced by ectopic
activation of MAPK p38
The above-mentioned results suggest that T3 could
down-regulate NF-B activity through the induction of
DUSP1 and the inhibition of MAPK p38 activity. If
MAPK p38 is causally involved in the regulation of the
NF-B response to TNF by T3 in GH4C1 cells, then its
activation should be sufficient for NF-B stimulation and
FIG. 3. T3 antagonizes the activation of the NF-B pathway by TNF.
A, GH4C1 cells were transiently transfected with a NF-B-driven
luciferase reporter plasmid (3 NF-B-TK-Luc) or the parental TK-Luc
plasmid (TK-Luc), and pRL-TK-Renilla, treated with T3 (5 nM) for 24 h
and then incubated in the absence or presence of 10 ng/ml TNF for
6 h. Cell extracts were prepared and assayed for luciferase and Renilla
activities. The luciferase levels were normalized to those of Renilla and
expressed as the induction over the controls. The data represent the
mean  SD of five independent experiments performed in duplicate.
B, Cells were transiently transfected with the pGal4-Luc reporter and
the pRL-TK-Renilla, together with Gal4–p65 or the parental Gal4-DBD
plasmid (DBD-Gal). Cells were then treated as in panel A, and
luciferase levels in the cell extracts were assayed, normalized with
Renilla, and expressed as the induction over controls. The data shown
represent the mean  SD of five independent experiments performed
in duplicate. C, Cells were incubated with T3 (5 nM) for 24 h and then
treated at different times with 10 ng/ml TNF. The cytosolic extracts
(CE) and the nuclear extracts (NE) were analyzed by Western blotting
using antibodies against IB, the phosphorylated form of IB
(pIB), and p65. Equal protein loading was evaluated with -actin.
The blots shown are from one representative experiment of three. D,
Cells were treated as in panel C, and nuclear extracts were prepared
and tested for NF-B binding activity by EMSA. The asterisk indicates a
nonspecific band. A representative experiment of three replicates is
shown. DBD, DNA-binding domain; Ren, Renilla.
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for T3-dependent repression. Accordingly, experiments
were carried out to determine the effect of T3 on NF-B
activity in cells transfected with a constitutively active
form of the activating kinase of MAPK p38, MAPK ki-
nase 6 (MKK6)EE. As shown in Fig. 4,MKK6EEwas able
to induce both NF-B-dependent transcription (Fig. 4A)
and p65 transactivation potential (Fig. 4B) significantly,
and incubation with T3 significantly reduced both re-
sponses, indicating that the hormone is able to inhibit the
activation of NF-B mediated by MAPK p38. As a con-
trol, the MKK6EE-induced activation of NF-B was re-
versed by the specific inhibitor SB203580, confirming
that NF-B is a target for the MAPK p38 pathway in
GH4C1 cells (Fig. 4, A and B). The kinase MSK1 is phos-
phorylated and activated by MAPK p38 and has been
suggested to be the main downstream effector for TNF-
mediated p65 transactivation potential (20). To further
investigate the mode of action of T3 on NF-B pathway
activity, p65 transactivation was first measured in cells
that were transfected either with a vector encoding for
wild-type MSK1, the MKK6EE mutant alone, or the
MKK6EE mutant plus wild-type MSK1 or two different
dominant-negative mutants of MSK1 (dn195 and dn565).
Although their overexpression was
quite high, neither basal nor MKK6EE-
induced p65 transactivation potential
was modified by either the wild-type
MSK1 or the two dominant-negative
mutants, and T3 was still able to re-
press the response to MKK6EE in all
groups (Fig. 4D). The activity of the
MSK1 proteinswas tested by analyzing
the transcriptional activity of a lucif-
erase reporter governed by the cAMP
response element binding protein
(CREB-Gal), which is a known MSK1
downstream target (26). As expected,
the activity of this reporter was in-
creased by MKK6EE plus wild-type
MSK1, whereas the expression of any
of the MSK1 dominant-negative mu-
tants abrogated the activity (Fig. 4E).
Furthermore, in agreement with our
previous findings showing that T3 can
antagonize CREB-dependent transcrip-
tion (27), we found that T3 also reduced
CREB-Gal activity. The overexpres-
sion of all MSK1 proteins was verified
in parallel Western blots (Fig. 4, D and
E, insets). To further verify thatMAPK
p38 was indeed involved in the regula-
tion of NF-B by TNF and T3, we
examined the effects of the specific in-
hibitor, SB203580, on the p65 transactivation potential
(Fig. 4C). As expected, the reduction of TNF-induced
p65 transactivation potential achieved by treatment with
either SB203580 or T3 was very similar and close to 50%
(Fig. 4C).
DUSP1 mediates the inhibitory effect of T3 on
stimulation of NF-B activity by TNF or by
MKK6EE expression
Considering that our data demonstrate that MAPK
p38 is involved in the regulation of NF-B activity by
TNF (Fig. 4), and that T3 blocks TNF-mediated acti-
vation of MAPK p38 through the induction of DUSP1
(Fig. 2), we next investigated whether DUSP1 affected the
NF-B activity in TNF-stimulated cells or in MKK6EE-
transfected cells. Our results show that overexpression of
a plasmid encoding DUSP1 reduced the NF-B-depen-
dent transcription induced by constitutively activeMKK6
(Fig. 5A) or by TNF (Fig. 5C). Similarly, DUSP1 over-
expression reduced the p65 transactivation potential in-
duced by transfecting cells with MKK6EE (Fig. 5B) or by
treatment with TNF (Fig. 5D). In all cases, T3 was still
FIG. 4. T3 blocks the NF-B pathway induced by ectopic activation of MAPK p38. A and B,
GH4C1 cells were transiently cotransfected with a vector encoding MKK6EE and pRL-TK-
Renilla, together with either a NF-B-driven luciferase reporter plasmid (3 NF-B-TK-Luc) (A)
or the pGal4-Luc reporter and Gal4-p65 (B). After the incubation with T3 (5 nM) or SB203580
(5 M) for 24 h, cell extracts were prepared and assayed for luciferase and Renilla activities.
The luciferase levels were normalized to those of Renilla and expressed as the induction over
the controls. The data show the mean  SD of three independent experiments performed in
duplicate. C, Cells were transiently transfected with the pGal4-Luc reporter, Gal4-p65, and
pRL-TK-Renilla. Cells were incubated with T3 (5 nM) or SB203580 (5 M) for 24 h and then
with 10 ng/ml TNF for 6 h. Cell extracts were prepared and assayed for luciferase and Renilla
activities as in panel A. D and E, Cells were transiently cotransfected with the pRL-TK-Renilla,
the pGal4-Luc reporter, and Gal4-p65 (D) or Gal4-CREB (E), together either with a vector
encoding wild type MSK1, MKK6EE alone, or MKK6EE plus a vector encoding wild type
MSK1, or the mutants MSK1dn195 or MSK1dn565. Cell incubations, cell extracts, and
measurement of luciferase and Renilla activities were performed as in panel A. The expression
level of MSK1 proteins is shown in the insets. Ren, Renilla; SB, SB203580; wt, wild type.
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able to reduce the NF-B activity, albeit to a lesser extent
than in control cells. To demonstrate the specificity of the
effect of DUSP1 overexpression on the NF-B-related-
reporter genes, we performed similar experiments using
either the TK-Luc control reporter or a luciferase reporter
gene driven by the collagenase promoter (73Col-Luc).
As shown in Fig. 5E, the activity of TK-Luc was not mod-
ified by either cell treatments or DUSP1 overexpression.
On the other hand, the activity of 73Col-Luc was not
changed by either TNF or T3 treatment, whereas DUSP1
overexpression, rather than inhibit the response to TNF,
significantly up-regulated it by about 4-fold (Fig. 5F).
These results demonstrate that DUSP1 overexpression
specifically down-regulates the activity of the NF-B-related-
reporter genes employed in this study.
To analyze the mechanism by which DUSP1 overex-
pression reduced NF-B activity, we examined the effect
of DUSP1 on TNF-induced nuclear translocation of
p65/NF-B. As shown in Fig. 5G, TNF significantly in-
creased p65/NF-B levels in nuclear extracts from control
cells, whereas the overexpression of DUSP1 partially sup-
pressed the effect of TNF. Accordingly, p65/NF-B
levels in cytosolic extracts were increased in DUSP1-
expressing cells (Fig. 5G). In agreement with the results
shown in Fig. 1D, the phosphatase was essentially absent
from nuclei in GH4C1 cells (Fig. 5G). These data suggest
that T3 inhibits, at least in part, the NF-B activity
through the induction of DUSP1 expression.
To assess the role of DUSP1 on inhibition of TNF-
mediated stimulation of NF-B by T3, cells were cotrans-
fected with the 3NF-B-Luc reporter and the siControl
or siDUSP1. The levels of DUSP1 mRNA were moni-
tored by QRT-PCR, demonstrating that siDUSP1 atten-
uated DUSP1 mRNA expression by 60% (Fig. 6A). In
addition, to confirm the knockdown of the protein,
DUSP1 protein levels were analyzed by Western blotting.
As expected, the transfectionwith the siDUSP1 abrogated
the T3-mediated-induction of DUSP1 both in control- and
TNF-treated cells (Fig. 6B). On the other hand, when the
FIG. 5. DUSP1 overexpression reduces the stimulation of NF-B
activity. A and B, GH4C1 cells were transiently cotransfected with a
vector encoding MKK6EE, a vector encoding DUSP1, and pRL-TK-
Renilla, together with either a NF-B-driven luciferase reporter plasmid
(3 NF-B-TK-Luc) (A) or the pGal4-Luc reporter and Gal4-p65 (B).
After the incubation with T3 (5 nM) for 24 h, cell extracts were
prepared and assayed for luciferase and Renilla activities as in Fig. 4.
The data shown represent the mean  SD of three independent
experiments performed in duplicate. C and D, GH4C1 cells were
transiently cotransfected with a vector encoding DUSP1, and pRL-TK-
Renilla, together with either the NF-B-driven luciferase reporter
plasmid (3 NF-B-TK-Luc) (C) or the pGal4-Luc reporter and Gal4-
p65 (D). Cells were incubated with T3 (5 nM) for 24 h and then with 10
ng/ml TNF for 6 h. Cell extracts and measurement of luciferase and
Renilla activities were performed as in panel A. E and F, GH4C1 cells
were transiently cotransfected with a vector encoding DUSP1, pRL-TK-
Renilla, together with either the TK-Luc plasmid (E) or the collagenase-
driven luciferase reporter plasmid (73Col-Luc) (F). Cells were
incubated with T3 (5 nM) for 24 h and then with 10 ng/ml TNF for
6 h. Cell extracts and measurement of luciferase and Renilla activities
were performed as in panel A. G, Cells were transfected with a vector
encoding DUSP1 and then incubated in the absence or presence of 10
ng/ml TNF for 1 h. The cytosolic extracts (CE) and the nuclear extracts
(NE) were analyzed by Western blotting using antibodies against p65
or DUSP1. Equal protein loading was evaluated with -actin. Ren,
Renilla.
FIG. 6. DUSP1 mediates the inhibitory effect of T3 on TNF-stimulated
NF-B activity. A, Cells were transfected with the siControl or the
siDUSP1, total RNA was extracted, and the levels of DUSP1 mRNA
were monitored by QRT-PCR. DUSP1 mRNA levels were normalized
with glyceraldehyde-3-phosphate dehydrogenase mRNA levels, and
the results are expressed as the fold change in mRNA expression. The
values represent the mean  SD. B, Cells were transfected as in panel
A, incubated for 24 h with T3, and then treated with 10 ng/ml TNF
for 6 h. and DUSP1 and -actin protein levels were analyzed in total
cell lysates by Western blotting. C, Cells were cotransfected with the
control siRNA or the DUSP1 siRNAs, together with the NF-B-driven
luciferase reporter plasmid (3 NF-B-TK-Luc), and treated as in B. Cell
extracts were prepared and assayed for luciferase and Renilla activities
as in Fig. 5.
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cells were incubated with T3, the TNF-induced-NF-B
transcription was reduced to about 50% of control cells,
whereas the inhibition by T3 was abolished in siDUSP1
transfected cells (Fig. 6C). These results demonstrate that
T3 regulates the TNF-activatedNF-B pathway through
the induction of DUSP1.
Discussion
In this report we show, for the first time, that T3 is able to
repress the activation ofMAPK p38 by TNF in pituitary
cells. Previous reports indicate that MAPK-dependent
pathways are present and active in pituitary cells and are
involved in gene transcription regulation stimulated by
some hormones and factors, such as IGF-I (28), GnRH
(29), or IL-1 (30). In many cells, MAPK p38 is described
as being activated by proinflammatory cytokines, such as
TNF, controlling diverse cellular functions. For exam-
ple, in the pituitary, it has been demonstrated that TNF
regulates apoptosis (8) or prolactin gene expression (9).
Here we demonstrate that this cytokine activates MAPK
p38 in pituitary cells without affecting ERK or JNK ac-
tivity, and, more interestingly, we show that T3 blocks the
stimulation of MAPK p38 activity by TNF. To date,
different nuclear receptors, such as the glucocorticoid re-
ceptor (31–33) or the peroxisome proliferator-activated
receptor- (34), have been shown to be antagonists of the
MAPK p38 pathway, but, to our knowledge, this is the
first report showing that the T3 receptors also have this
effect.
Many signaling pathways can interact with each other
through biochemical cross talk. For example, MAPK p38
and NF-B are known to be activated in response to sim-
ilar stimuli, including inflammatory cytokines, phorbol
esters, bacterial toxins, viruses, or UV light in different
cell types. In fact, it is well known that NF-B is a MAPK
p38 target in response to TNF in different cell types (35).
Stimulation of NF-B activates the IK signalsome that
phosphorylates IB and NF-B proteins, leading to ubiq-
uitination and degradation of IB, and to subsequent
translocation of free NF-B dimers to the nucleus. In
agreement with this, we found rapid IB phosphoryla-
tion and transient nuclear translocation of p65/NF-B,
together with an increase in NF-B-mediated transcrip-
tion and p65/NF-B transactivation potential in TNF-
stimulated GH4C1 cells. These results are in agreement
with those obtained in other pituitary cell lines (9, 17) and
reinforce the idea that TNFmight act as an autocrine or
paracrine regulator of pituitary cell function (6–8).
However, the interactions between MAPK p38 and
NF-B are not well understood, and they have never been
investigated in pituitary cells. Here we demonstrate that
MAPK p38 plays an important role on NF-B activation
in GH4C1 cells. Previous reports have shown that over-
expression or activation of MAPK p38 leads to the deg-
radation of IB and its dissociation fromNF-B, thereby
allowing p65/NF-B nuclear translocation and DNA
binding in NIH3T3 cells (36), in C2C12 cells (37), or in
L929 cells (18). In agreement with these reports, our data
show that ectopic activation of MAPK p38 induces the
NF-B pathway in GH4C1 cells. Interestingly, this acti-
vation does not appear to be controlled by the down-
stream effector MSK1, which has been described as the
main mediator of NF-B regulation by MAPK p38 in
other cellular systems (20).
Functional cross talk between nuclear receptors and
NF-B has been reported for various classes of receptors
and has been shown to be crucial for regulation of many
cellular functions (36, 38–40). Nuclear receptors can in-
hibit the action of NF-B in the presence of their cognate
ligands by a variety of mechanisms, and we show here
that T3 inhibits NF-B-dependent transcription induced
by TNF in GH4C1 cells by affecting the phosphoryla-
tion of IB, the translocation of active NF-B complexes
from the cytosol to the nucleus, the binding of p65/NF-B
to B sequences in DNA, and p65/NF-B transactivation.
Surprisingly, T3 impaired the phosphorylation of IB
without affecting its degradation. Although we do not
have a good explanation for this observation, we can
speculate that this apparent discrepancy could be ex-
plained in light of the rapid turnover of this protein by
resynthesis after TNF treatment, which could hinder
observation of the differences between control- and T3-
treated cells. Alternatively, T3 could affect the activation
of NF-B by a mechanism that is independent of the deg-
radation of IB, as previously described (41–43). Simi-
lar to what happened in TNF-stimulated cells, we show
that T3 is able to inhibit both the NF-B-dependent tran-
scription and the p65/NF-B transactivation induced by
expression of the constitutively active mutant of MKK6.
These findings altogether indicate that the effect of T3 on
the NF-B pathway is mediated, at least in part, by regu-
lation of MAPK p38 and seems to be proximal to MAPK
p38 itself. The hormone must block MAPK p38 activa-
tion, even when the stimulus is provided by a constitu-
tively active upstream kinase. In addition, these results
strongly suggest that the inhibitory effect of T3 on TNF-
induced NF-B activity could be also mediated byMAPK
p38 regulation. In fact, this hypothesis is very plausible,
taking into account that TNF specifically activates
MAPK p38 in GH4C1 cells and that T3 significantly re-
duces this induction in a time-dependent manner. More-
over, the fact that both T3 and the specific MAPK p38
inhibitor SB203580 repress TNF-induced p65/NF-B
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transactivation to a similar extent reinforces this hypothesis.
Different nuclear receptors have been shown to regulate
both the NF-B pathway and the MAPK p38-signaling
cascade. For example, dexamethasone synergistically en-
hances IL-1-induced Toll-like receptor 2 expression via
negative cross talk with the MAPK p38 pathway and
NF-B activation (44). On the other hand, PPAR re-
duces proinflammatory cytokines expression by antago-
nizing the activity of MAPK p38 (34) and by interfering
with NF-B (45). Moreover, estradiol blocks the hypoxia-
mediated activation of both MAPK p38 and NF-B-
dependent transcription (46). In agreement with all these
reports, our data show that T3 can also block both the
NF-B pathway and MAPK p38 phosphorylation in-
duced by TNF in pituitary cells.
DUSP1 is a phosphatase that is gaining interest as an
antiinflammatory molecule because it impairs the re-
sponse achieved by diverse proinflammatory agents in-
cluding TNF (47, 48). Using the siRNA approach to
selectively inhibit DUSP1 expression, we demonstrate in
this report that the effect of T3 on TNF-induced MAPK
p38 and NF-B activation is mediated by this phospha-
tase, because DUSP1 depletion abrogates the effect of
the hormone. We also used a converse approach, namely
DUSP1 overexpression, and showed that NF-B activa-
tion by either TNF or ectopic expression of the upstream
inducer of MAPK p38 was almost abrogated, whereas T3
continued to inhibit theNF-B activity. Taking the effects
of DUSP1 knockdown and DUSP1 overexpression to-
gether, we conclude that DUSP1 is an important mediator
of the T3-induced inhibition of both the MAPK p38- and
the NF-B-signaling pathways. Several reports have
shown an inhibition of the NF-B signaling pathway con-
comitant with an induction of the expression of DUSP1 in
diverse cellular systems (49–51). However, the existence
of both events at the same time was only circumstantial in
all cases. By contrast, we had shown that DUSP1 governs
T3-mediated inhibition of the NF-B pathway in serum-
deprived GH4C1 cells (25), and in this report we demon-
strate that this is also true for TNF-stimulation. Regu-
lation of the NF-B pathway by DUSP1 is not surprising
considering that this protein has been identified as one of
the components of the IKK signalsome. Indeed, DUSP1
coassociates with IKK, and it was speculated that
DUSP1 (or the DUSP1-reactive protein identified in the
IKK signalsome) might be the phosphatase responsible
for down-regulating IKK/ activity (52–54). This hy-
pothesis could explain our data showing that T3 inhibits
NF-B through a mechanism dependent on DUSP1 ex-
pression. To study this possibility, we have performed
experiments to analyze the possible interaction between
DUSP1 and IKK/ in GH4C1 cells, and our preliminary
data show that TNF, alone or in combination with T3, is
able to induce the association between DUSP1 and
IKK/ (data not shown). On the other hand, our results
show that the pool of up-regulatedDUSP1 by T3 ismainly
localized to the cytosol, suggesting that T3-induced-
DUSP1 specifically affects proteins that are located at this
compartment. Subcellular localization is an important
regulatory feature of DUSP1. Despite the fact that the
nuclear distribution of DUSP1 is known in many systems,
the mechanisms regulating its localization remain poorly
defined. It has been suggested that the two basic clusters
in the amino terminus of DUSP1, which are critical for
binding toMAPK p38 (55), also serve to target DUSP1 to
the nucleus (12). Thus, it is conceivable that, upon T3
treatment, the basic clusters of DUSP1 bind to the cyto-
solic pool of MAPK p38, hindering complete nuclear lo-
calization of DUSP1. Alternatively, DUSP1 may interact
with other proteins through its LXXLLmotif, which may
retain DUSP1 in the cytosolic compartment. These find-
ings altogether strongly suggest that DUSP1 could inhibit
the NF-B pathway by regulating IK activity through its
interaction with the IK signalsome, although the under-
lying mechanism requires further investigation.
In conclusion, we have shown, for the first time, that
T3 can antagonize the TNF signaling pathway in pitu-
itary cells by a mechanism that involves the induction of
DUSP1. Both T3 and TNF have been shown to be pro-
duced locally in the pituitary gland, suggesting that this
effect could be important for pituitary physiology in vivo.
Moreover, the fact that T3 regulates the effects of TNF
on bothMAPKp38 andNF-B activation inGH4C1 cells
opens new perspectives in the study of the role of T3 as an
antiinflammatory ligand controlling TNF effects in the
pituitary.
Materials and Methods
Materials and plasmids
Tissue culture media and sera were obtained from Life Tech-
nologies, Inc. (Gaithersburg, MD). The antibodies used were:
anti-NF-B/p65, anti-IB, anti-MKP1, anti-p38 MAPK, anti-
ERK2, anti-JNK1, and anti-poly ADP ribose polymerase (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA); antiphospho-IB,
antiphospho-ERK and antiphospho-p38 MAPK (Cell Signaling
Technology, Danvers, MA); antihemagglutinin (Covance Re-
search Products, Princeton, NJ); antiphospho-JNK (Promega
Corp., Madison, WI); anti--actin, anti-Flag, and antitubulin
(Sigma Chemical Co., St. Louis, MO); and peroxidase-conju-
gated secondary antibodies (Santa Cruz Biotechnology).
SB203580 was from Calbiochem (La Jolla, CA). T3 was from
Sigma. Rat TNF was from PreProTech (Rocky Hill, NJ). The
3NF-B-TK-Luc reporter plasmid, which contains a three tan-
dem repeat of the NF-B-binding motif of the H-2k gene up-
stream of the thymidine kinase minimal promoter (56), was
kindly provided by Dr. M. Fresno (Centro de Biología Molecu-
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lar Severo Ochoa, Consejo Superior de Investigaciones Cienti-
ficas-UAM, Madrid, Spain). The plasmid containing the Gal4-
DNA-binding domain fused to the full-length human p65/
NF-B coding sequence (pGal4-p65) (57) was obtained from
the Belgian Coordinated Collections of Microorganisms
(BCCM/LMBP Plasmid Collection) (Ghent, Belgium). The plas-
mid pGal4-Luc and the probe for EMSAs (58) were kindly pro-
vided byDr. R. Perona (Instituto de Investigaciones Biome´dicas,
CSIC-UAM, Madrid, Spain). The plasmids pCMV-Flag-MKP1
and pcDNA3-HA-MKK6EE (with Ser-to-Glu and Thr-to-Glu
mutations at codons 207 and 211) were kindly provided by Dr.
A. Clark (Imperial College, London, UK). The plasmids
pCMV5-Flag-Msk1 wild type, pCMV5-Flag-D195/A-Msk1
(with an Asp-to-Ala mutation at codon 195), and pCMV5-Flag-
D565/A-Msk1 (with an Asp-to-Ala mutation at codon 565)
were kindly provided by Dr. D. Alessi (The University of
Dundee, Scotland, UK).
Cell culture and transfection
GH4C1 cells were cultured in DMEM supplemented with
10% fetal bovine serum. In the experiments, the cell medium
was replaced by fresh medium containing 0.1% AG18 resin
and charcoal-stripped fetal bovine serum, and cells were incu-
bated in the presence or absence of T3 (5 nM) and with or
without TNF (10 ng/ml) as indicated. Control cells were incu-
bated with the same volume of the vehicle used to dissolve the
different compounds.
GH4C1 cells were transfected by electroporation, as de-
scribed previously (59) with minor modifications (25).
NF-B reporter assays
The NF-B reporter assay was performed as described pre-
viously (25) with minor modifications. Cells were transfected as
described, and the reporter assays were performed 24 h later.
Each experiment was repeated at least three times with similar
differences in regulated expression, and all data are expressed as
the mean  SD.
Cell extracts and Western blot analysis
Nuclear and total cell extracts were prepared as described
previously (25). For Western blot analysis, cells were incubated
as described in the figure legends and then harvested in lysis
buffer (25). The protein content of the cell or nuclear extracts
was normalized, and the samples were separated by SDS-PAGE
and then transferred to nitrocellulose membranes. The mem-
branes were probed with the primary antibodies indicated and
were detected with a peroxidase-coupled secondary antibody. An-
tibody binding was visualized using the enhanced chemilumines-
cence system (Amersham Pharmacia Biotech, Piscataway, NJ).
EMSA
After cell treatment, DNA binding was assessed by EMSA as
previously described (25).
Real-time quantitative RT-PCR
They were performed as previously described (25).
Statistical analysis
All data are expressed as means  SD. In statistical analysis,
Student’s t testwas performed using the SSC-Stat software (version
2.18; University of Reading, Reading, UK). The statistical signifi-
cance of difference between groups was expressed by asterisks
(*, 0.01 P 0.05; **, 0.001 P 0.01; ***, P 0.001).
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